The utility of prostate-specific antigen in the management of advanced prostate cancer

BJU International

Volumn 112, Issue 5, 2013, Pages 548-560

  Crawford, E David ^a   Bennett, Charles L ^b   Andriole, Gerald L ^c   Garnick, Marc B ^d   Petrylak, Daniel P ^e  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b University of South Carolina   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

advanced prostate cancer; androgen deprivation therapy; patient management; prostate specific antigen

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; BICALUTAMIDE; DOCETAXEL; ENZALUTAMIDE; ESTRAMUSTINE; FLUTAMIDE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GOSERELIN; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SIPULEUCEL T; TESTOSTERONE; ZOLEDRONIC ACID;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HUMAN; METASTASIS FREE SURVIVAL; MONOTHERAPY; ONCOLOGICAL PARAMETERS; ORCHIECTOMY; OVERALL SURVIVAL; PATIENT MONITORING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATE SPECIFIC ANTIGEN DOUBLING TIME; RADICAL RETROPUBIC PROSTATECTOMY; REVIEW; TESTOSTERONE BLOOD LEVEL;

ADVANCED PROSTATE CANCER; ANDROGEN-DEPRIVATION THERAPY; PATIENT MANAGEMENT; PROSTATE-SPECIFIC ANTIGEN;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; HUMANS; MALE; NEOPLASM STAGING; ORCHIECTOMY; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84882277213     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12061     Document Type: Review

References (91)

1. Hernandez J, Thompson IM,. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer 2004; 101: 894-904
2. Ablin RJ, Pfeiffer L, Gonder MJ, Soanes WA,. Precipitating antibody in the sera of patients treated cryosurgically for carcinoma of the prostate. Exp Med Surg 1969; 27: 406-410
3. Nadji M, Tabei SZ, Castro A, et al. Prostatic-specific antigen: an immunohistologic marker for prostatic neoplasms. Cancer 1981; 48: 1229-1232
4. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156-1161
5. Chou R, Croswell JM, Dana T, et al. Screening for prostate cancer: a review of the evidence for the u.s. Preventive services task force. Ann Intern Med 2011; 155: 762-771
6. Miller DC, Hollenbeck BK,. Missing the mark on prostate-specific antigen screening. JAMA 2011; 306: 2719-2720
7. AUA. Prostate-Specific Antigen Best Practice Statement: 2009 Update. Linthicum, MD: American Urological Association Education and Research, Inc., 2009
8. National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Prostate Cancer, Version 1. 2012. Available at: http://www.nccn.org/ professionals/physician-gls/pdf/prostate.pdf. Accessed March, 2012
9. Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59: 61-71
10. Smith MR, Kabbinavar F, Saad F, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 2918-2925
11. Critz FA, Williams WH, Benton JB, Levinson AK, Holladay CT, Holladay DA,. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol 2000; 163: 1085-1089
12. Vickers AJ, Savage C, O'Brien MF, Lilja H,. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 2009; 27: 398-403
13. Svatek RS, Shulman M, Choudhary PK, Benaim E,. Critical analysis of prostate-specific antigen doubling time calculation methodology. Cancer 2006; 106: 1047-1053
14. Arlen PM, Bianco F, Dahut WL, et al. Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol 2008; 179: 2181-2186
15. Fitzpatrick JM, Banu E, Oudard S,. Prostate-specific antigen kinetics in localized and advanced prostate cancer. BJU Int 2009; 103: 578-587
16. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433-439
17. Antonarakis ES, Chen Y, Elsamanoudi SI, et al. Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database. BJU Int 2011; 108: 378-385
18. Antonarakis ES, Feng Z, Trock BJ, et al. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int 2012; 109: 32-39
19. D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH,. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003; 95: 1376-1383
20. Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011; 59: 572-583
21. Stewart AJ, Scher HI, Chen MH, et al. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J Clin Oncol 2005; 23: 6556-6560
22. Rodrigues NA, Chen MH, Catalona WJ, Roehl KA, Richie JP, D'Amico AV,. Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer. Cancer 2006; 107: 514-520
23. D'Amico AV, McLeod DG, Carroll PR, Cullen J, Chen MH,. Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality. Cancer 2007; 109: 1290-1295
24. USA Food and Drug Admisitration. Oncologic Drugs Advisory Committee Briefing Document. Issues Concerning the Development of Products for the Treatment of Patients with Non-Metastatic Castration-Resistant Prostate Cancer, 14 September 2011. Available at: http://www.fda.gov/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/ucm271469.htm. Accessed January 2013
25. USA Food and Drug Administration. Transcript for the September 14, 2011 Meeting of the Oncologic Drugs Advisory Committee (NM-CRPC-PM Session). Available at: http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM277463.pdf. Accessed January 2013
26. Armstrong AJ, Garrett-Mayer ES, Yang YC, de, Wit R, Tannock IF, Eisenberger M,. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 2007; 13: 6396-6403
27. Daskivich TJ, Regan MM, Oh WK,. Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy. Urology 2007; 70: 527-531
28. Oudard S, Banu E, Scotte F, et al. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Ann Oncol 2007; 18: 1828-1833
29. Semeniuk RC, Venner PM, North S,. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer. Urology 2006; 68: 565-569
30. Chung CS, Chen MH, Cullen J, McLeod D, Carroll P, D'Amico AV,. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality. Urology 2008; 71: 136-140
31. Ross RW, Xie W, Regan MM, et al. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer 2008; 112: 1247-1253
32. Soga N, Arima K, Sugimura Y,. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade. Jpn J Clin Oncol 2008; 38: 617-622
33. Soga N, Onishi T, Arima K, Sugimura Y,. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy. Int J Urol 2007; 14: 192-197
34. Hussain M, Tangen CM, Higano C, et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006; 24: 3984-3990
35. Park SC, Rim JS, Choi HY, et al. Failing to achieve a nadir prostate-specific antigen after combined androgen blockade: predictive factors. Int J Urol 2009; 16: 670-675
36. Huang SP, Bao BY, Wu MT, et al. Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy. Prostate 2011; 71: 1189-1197
37. Huang SP, Bao BY, Wu MT, et al. Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy. Aging Male 2012; 15: 34-41
38. Kwak C, Jeong SJ, Park MS, Lee E, Lee SE,. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J Urol 2002; 168: 995-1000
39. Sasaki T, Onishi T, Hoshina A,. Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis. Prostate Cancer Prostatic Dis 2011; 14: 248-252
40. Morote J, Trilla E, Esquena S, Abascal JM, Reventos J,. Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer. Int J Cancer 2004; 108: 877-881
41. Saad F, Segal S, Eastham J,. Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid. Eur Urol 2012. DOI: 10.1016/j.eururo.2012.05.007 [Epub ahead of print]
42. Smith MR, Cook R, Lee KA, Nelson JB,. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer 2011; 117: 2077-2085
43. Benaim EA, Pace CM, Lam PM, Roehrborn CG,. Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer. Urology 2002; 59: 73-78
44. Scholz M, Lam R, Strum S, Jennrich R, Johnson H, Trilling T,. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals. Urology 2007; 70: 506-510
45. Choueiri TK, Xie W, D'Amico AV, et al. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer 2009; 115: 981-987
46. Park YH, Hwang IS, Jeong CW, Kim HH, Lee SE, Kwak C,. Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer. J Urol 2009; 181: 2520-2525
47. Yu EY, Gulati R, Telesca D, et al. Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. J Clin Oncol 2010; 28: 2668-2673
48. Keizman D, Huang P, Antonarakis ES, et al. The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation. Prostate 2011; 71: 1608-1615
49. Hori S, Jabbar T, Kachroo N, Vasconcelos JC, Robson CN, Gnanapragasam VJ,. Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer. J Cancer Res Clin Oncol 2011; 137: 235-241
50. Miyamoto S, Ito K, Miyakubo M, et al. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy. Prostate Cancer Prostatic Dis 2012; 15: 75-86
51. Ryan CJ, Smith A, Lal P, et al. Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression. Urology 2006; 68: 834-839
52. Prentice RL,. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8: 431-440
53. D'Amico AV, Chen MH, de, Castro M, et al. Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. Lancet Oncol 2012; 13: 189-195
54. Petrylak DP, Ankerst DP, Jiang CS, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006; 98: 516-521
55. Ray ME, Bae K, Hussain MH, Hanks GE, Shipley WU, Sandler HM,. Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial. J Natl Cancer Inst 2009; 101: 228-236
56. Berruti A, Mosca A, Tucci M, et al. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer 2005; 12: 109-117
57. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008; 102: 1531-1538
58. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17: 3461-3467
59. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-1159
60. Hussain M, Goldman B, Tangen C, et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol 2009; 27: 2450-2456
61. Halabi S, Vogelzang NJ, Ou SS, Owzar K, Archer L, Small EJ,. Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J Clin Oncol 2009; 27: 2766-2771
62. Scher HI, Morris MJ, Basch E, Heller G,. End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol 2011; 29: 3695-3704
63. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520
64. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512
65. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005
66. Suzuki H, Okihara K, Miyake H, et al. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 2008; 180: 921-927
67. Okihara K, Ukimura O, Kanemitsu N, Mizutani Y, Kawauchi A, Miki T,. Clinical efficacy of alternative antiandrogen therapy in Japanese men with relapsed prostate cancer after first-line hormonal therapy. Int J Urol 2007; 14: 128-132
68. Keizman D, Huang P, Carducci MA, Eisenberger MA,. Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression. Prostate 2012; 72: 461-467
69. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 2007; 25: 3965-3970
70. Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27: 3742-3748
71. Danila DC, Morris MJ, de, Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010; 28: 1496-1501
72. Reid AH, Attard G, Danila DC, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010; 28: 1489-1495
73. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375: 1437-1446
74. Berthold DR, Pond GR, Roessner M, de, Wit R, Eisenberger M, Tannock AI,. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 2008; 14: 2763-2767
75. Ryan CJ, Shah S, Efstathiou E, et al. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res 2011; 17: 4854-4861
76. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-422
77. Huber ML, Haynes L, Parker C, Iversen P,. Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst 2012; 104: 273-279
78. Schalken JA,. Molecular and cellular prostate biology: origin of prostate-specific antigen expression and implications for benign prostatic hyperplasia. BJU Int 2004; 93 (Suppl. 1): 5-9
79. Takizawa I, Nishiyama T, Hara N, Isahaya E, Hoshii T, Takahashi K,. Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: tumor malignant potential and androgen milieu. Prostate 2010; 70: 1395-1401
80. Bruchovsky N, Klotz L, Crook J, Goldenberg SL,. Locally advanced prostate cancer-biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy. Cancer 2007; 109: 858-867
81. Page ST, Lin DW, Mostaghel EA, et al. Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 2006; 91: 3850-3856
82. Mostaghel EA, Page ST, Lin DW, et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 2007; 67: 5033-5041
83. Bonkhoff H, Berges R,. From pathogenesis to prevention of castration resistant prostate cancer. Prostate 2010; 70: 100-112
84. Locke JA, Guns ES, Lubik AA, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 2008; 68: 6407-6415
85. Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004; 64: 9209-9216
86. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008; 68: 4447-4454
87. Dinnes J, Hewison J, Altman DG, Deeks JJ,. The basis for monitoring strategies in clinical guidelines: a case study of prostate-specific antigen for monitoring in prostate cancer. CMAJ 2012; 184: 169-177
88. Rove KO, Debruyne FM, Djavan B, et al. Role of testosterone in managing advanced prostate cancer. Urology 2012; 80: 754-762
89. Leibovici D, Spiess PE, Agarwal PK, et al. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer 2007; 109: 198-204
90. Kinebuchi Y, Noguchi W, Irie K, Nakayama T, Kato H, Nishizawa O,. Relapsed prostate cancer with neuroendocrine differentiation and high serum levels of carcinoembryonic antigen without elevation of prostrate-specific antigen: a case report. Int J Urol 2007; 14: 147-149
91. Wang W, Epstein JI,. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol 2008; 32: 65-71